Department of Psychiatry, University of Calgary, Calgary, AB, Canada.
Expert Opin Pharmacother. 2023 Sep-Dec;24(18):1957-1961. doi: 10.1080/14656566.2023.2288287. Epub 2024 Jan 5.
A novel new area of exploration in the treatment of bipolar disorder is the gut brain axis. Studies have shown significant differences between the gut microbiome in those with bipolar disorder and those without the illness, as well as documented microbiome changes associated with the effects of bipolar pharmacotherapy and targeted microbial interventions. Although we have evidence suggesting the bi-directional relationship between the gut microbiome and psychiatric disorders, we are still unable to utilize this understanding clinically.
We need to better understand the factors that impact the microbiome in this illness and vice versa.
Additionally, changes in gut microbiome in bipolar disorder might be used for biomarker identification with a potential to help in diagnosis and monitoring of the condition. It is an important area for further research and may provide improved therapeutic outcomes.
在双相情感障碍的治疗中，一个新的探索领域是肠道-大脑轴。研究表明，双相情感障碍患者和无病患者的肠道微生物组存在显著差异，并且记录了与双相情感障碍药物治疗和靶向微生物干预相关的微生物组变化。尽管我们有证据表明肠道微生物组与精神障碍之间存在双向关系，但我们仍然无法在临床上利用这一认识。
我们需要更好地了解影响这种疾病中微生物组的因素，反之亦然。
此外，双相情感障碍中肠道微生物组的变化可用于生物标志物的识别，有可能有助于诊断和监测病情。这是一个需要进一步研究的重要领域，可能提供改善的治疗结果。
